

REVIEW OF ATENOLOL USE IN PATIENTS WITH HEART FAILURE

M. Flores Fernández, , D. García González, J. Ayala Álvarez Canal,
A. Fernández Vázquez, D. Ozcoidi Idoate, M. Barba Llacer,
L. Mira Bayón, M. Tejada García, M.C. Arenós Monzó, J.J. Ortiz De Urbina González

Hospital Pharmacy Service. Complejo Asistencial Universitario de León (CAULE). León (Spain).

BACKGROUND

Beta-blockers are a cornerstone therapy in chronic heart failure. Only bisoprolol, metoprolol, carvedilol and nebivolol have an approved indication for this condition. Atenolol is not indicated in heart failure, which may lead to potentially inappropriate prescribing.

OBJECTIVES

To identify hospitalized patients with heart failure treated with atenolol and evaluate the acceptance of a pharmacist-led intervention recommending substitution with an approved beta-blocker.

MATERIAL AND METHODS


- ❖ Cross-sectional study conducted in a tertiary care hospital (December 2024 – April 2025).
- ❖ Hospitalized patients receiving atenolol were reviewed. If heart failure was detected, physicians were informed and advised to switch to a **beta-blocker with approved indication.**

Variables collected


Demographics (age, sex)
Clinical data (service, CVRF)
Atenolol dose
Pre-admission prescription
Acceptance of intervention

RESULTS


INTERVENTION



CLINICAL SERVICE PRESCRIBING ATENOLOL IN HEART FAILURE



CARDIOVASCULAR RISK FACTORS AMONG PATIENTS



CONCLUSIONS

In our hospital, nearly 1 in 10 patients on atenolol had heart failure. The review of treatment by the pharmacist allowed for the detection of these cases, which were fully accepted by the responsible physicians.